Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 3/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | PPP5C | P53041 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17867785 | 1.00 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL16148734 | 0.87 | LGALS8 (0.51) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL16148735 | 0.87 | LGALS8 (0.51) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL19772749 | 0.85 | LGALS8 (0.53) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL469613 | 0.85 | LGALS8 (0.53) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL24155775 | 0.85 | LGALS8 (0.53) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL21426768 | 0.85 | SELP (0.47) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL1842874 | 0.83 | LGALS8 (0.47) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL3392883 | 0.83 | LGALS8 (0.47) | MAPK1LGALS8LGALS3LGALS4GBA1 | |
| SCHEMBL20306671 | 0.82 | LGALS8 (0.49) | MAPK1LGALS8LGALS3LGALS4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925654-B2 | Esters of 2-deoxy-monosaccharides with anti proliferative activity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220023326-A1 | ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | UNIV TEXAS (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3939595-A1 | ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | Board of Regents, The University of Texas System (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11026960-B2 | Esters of 2-deoxy-monosaccharides with anti proliferative activity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190224225-A1 | ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-07-25 | — | — | US | disclosed |
| US-10201554-B2 | Esters of 2-deoxy-monosacharides with anti proliferative activity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160184336-A1 | ESTERS OF 2-DEOXY-MONOSACHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201554-B2 | Esters of 2-deoxy-monosacharides with anti proliferative activity | DERA, G6PD, HK2 | MAPK1 1570/4885LGALS8 881/4885LGALS3 1115/4885 |
| US-11925654-B2 | Esters of 2-deoxy-monosaccharides with anti proliferative activity | SLC2A2, SLC2A1, SLC2A4 | MAPK1 1486/4885LGALS8 1075/4885LGALS3 1030/4885 |
| US-20190224225-A1 | ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | SLC2A2, SLC2A1, SLC2A4 | MAPK1 1486/4885LGALS8 1075/4885LGALS3 1030/4885 |
| US-11026960-B2 | Esters of 2-deoxy-monosaccharides with anti proliferative activity | SLC2A2, SLC2A1, SLC2A4 | MAPK1 1486/4885LGALS8 1075/4885LGALS3 1030/4885 |
| US-20160184336-A1 | ESTERS OF 2-DEOXY-MONOSACHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | DERA, G6PD, HK2 | MAPK1 1570/4885LGALS8 881/4885LGALS3 1115/4885 |
| US-20220023326-A1 | ESTERS OF 2-DEOXY-MONOSACCHARIDES WITH ANTI PROLIFERATIVE ACTIVITY | SLC2A2, SLC2A1, SLC2A4 | MAPK1 1486/4885LGALS8 1075/4885LGALS3 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.